<DOC>
	<DOC>NCT01009060</DOC>
	<brief_summary>This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with schizophrenia</brief_summary>
	<brief_title>Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia</brief_title>
	<detailed_description>This is a 7-week, Phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group design study in male and female subjects with schizophrenia who are stabilised on antipsychotic medication. Subjects will be randomised to receive either GSK239512 or placebo for 7 weeks. They will undergo weekly review of safety, tolerability and cognitive performance measures.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1. Clinical diagnosis of Schizophrenia 2. No acute exacerbation of symptoms requiring hospital admission or step up care in the previous six months. 3. Not on any symptomatic treatment for cognition 1. Poses a significant homicidal or suicidal risk or evidence of previous homicidal or suicidal risk. 2. Comorbid psychiatric or significant physical illness 3. Alcohol or drug abuse or dependence.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>H3 Antagonist</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>double blind</keyword>
	<keyword>Histamine</keyword>
	<keyword>randomised</keyword>
	<keyword>placebo controlled</keyword>
	<keyword>Cognition</keyword>
</DOC>